Your browser doesn't support javascript.
loading
CD83 expression characterizes precursor exhausted T cell population.
Wu, Zhiwen; Yoshikawa, Toshiaki; Inoue, Satoshi; Ito, Yusuke; Kasuya, Hitomi; Nakashima, Takahiro; Zhang, Haosong; Kotaka, Saki; Hosoda, Waki; Suzuki, Shiro; Kagoya, Yuki.
Afiliação
  • Wu Z; Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Yoshikawa T; Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Inoue S; Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
  • Ito Y; Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Kasuya H; Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Nakashima T; Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
  • Zhang H; Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Kotaka S; Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Hosoda W; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Suzuki S; Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Kagoya Y; Division of Cellular Oncology, Department of Cancer Diagnostics and Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Commun Biol ; 6(1): 258, 2023 03 11.
Article em En | MEDLINE | ID: mdl-36906640
T cell exhaustion is a main obstacle against effective cancer immunotherapy. Exhausted T cells include a subpopulation that maintains proliferative capacity, referred to as precursor exhausted T cells (TPEX). While functionally distinct and important for antitumor immunity, TPEX possess some overlapping phenotypic features with the other T-cell subsets within the heterogeneous tumor-infiltrating T-lymphocytes (TIL). Here we explore surface marker profiles unique to TPEX using the tumor models treated by chimeric antigen receptor (CAR)-engineered T cells. We find that CD83 is predominantly expressed in the CCR7+PD1+ intratumoral CAR-T cells compared with the CCR7-PD1+ (terminally differentiated) and CAR-negative (bystander) T cells. The CD83+CCR7+ CAR-T cells exhibit superior antigen-induced proliferation and IL-2 production compared with the CD83- T cells. Moreover, we confirm selective expression of CD83 in the CCR7+PD1+ T-cell population in primary TIL samples. Our findings identify CD83 as a marker to discriminate TPEX from terminally exhausted and bystander TIL.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Subpopulações de Linfócitos T / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Commun Biol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Subpopulações de Linfócitos T / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Commun Biol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão